


Pharmaceutical Department

2016

Annual Report





2016 Annual Report

Pharmaceutical Department

Faculty • Full Members: William E. Evans, PharmD; William Greene, PharmD; Mary V. Relling, PharmD (chair); Erin G. Schuetz, PhD; John D. Schuetz, PhD, Clinton F. Stewart, PharmD; Associate Members: James M. Hoffman, PharmD ; Jun J. Yang, PhD; Assistant Member: Daniel Savic, PhD; Research Associate: Liqin Zhu, PhD

Staff Scientists • Barthelemy Diouf, PhD; Amarjit Chaudhry, PhD; John Lynch, PhD; Yu Fukuda, PhD
Laboratory Directors • Alejandro Molinelli, PhD; Kristine R. Crews, PharmD

Fellows • Ju Bao, PhD; Jordan Beard, PhD; Emily Finch, PhD; Yoshihiro Gocho, MD, PhD; Charnise Goodings, PhD; Zachary Jones, PhD; Seth Karol, MD; Chengcheng Liu, PhD; Yiwei Liu, PhD; Elixabet Lopez Lopez, PhD; Robert McCorkle, PhD; Takaya Moriyama, MD, PhD; Yogesh Patel, PhD; Aaron Pitre, PhD; Maoxiang Qian, PhD; Aksana Vasilyeva, PhD; Juwina Wijaya, PhD; Hui Zhang, MD, PhD

Residents • Jennifer Hockings, PharmD, PhD; Nick Lockhart, PharmD; Deni Trone, PharmD, PhD; Dagny Ulrich, PharmD, PhD

Graduate Students • R.J. Autry, Ashley Crumby, Samit Ganguly, Nick Keeling, Xujie Zhao

Overview:

The primary goal of the Pharmaceutical Sciences Department is to improve therapy for children with catastrophic diseases by elucidating the basis for interpatient variability in response to medications. Survival rates for children with cancer, hematologic disorders, HIV infection, or other serious diseases continue to increase, largely through the improved use of medications. Failure of current therapies and unacceptable adverse effects are partly due to less-than optimal prescribing. Our goal is to elucidate the biological basis of interindividual differences in pharmacologic response, and to translate our findings into improving patient care.

Heterogeneity in the metabolism, transport, elimination, targets, and receptors of many drugs and consequent variability in therapeutic or adverse effects may result from germline genetic differences or genetic alterations in malignant cells. Drug response is also influenced by nongenetic factors (e.g., drug interactions, host organ function and maturity, disease severity, adherence to therapy).

We develop preclinical models to systematically characterize the determinants of human variation in drug response, and we integrate our work into translational clinical studies (Figure 1). Laboratory work informs clinical studies, and clinical problems drive much of the laboratory work. Faculty members lead and participate in interdisciplinary St. Jude programs and national cooperative research collaborations. Our pharmacogenetic research integrates genome-wide analyses, molecular




Figure 1. With responsibility for medications, the use of clinical data, and the development of clinical and research laboratory tests, knowledge is used to provide the best possible care for St. Jude patients while making discoveries with implication outside of St. Jude.

analyses, functional genomics, pharmacokinetics, and pharmacodynamics to identify genetic determinants of drug effects, with the long-term goal of optimizing therapy for individual patients. The Department comprises both Pharmaceutical Sciences and Pharmaceutical Services, and includes ten faculty members, 15-25 post-doctoral fellows (Figure 2) and residents (Figure 9), 10-20 undergraduate and graduate students, over 45 pharmacists, and over 110 full time staff members working as computing experts, research nurses, technical, laboratory, administrative, and clinical staff. The department is supported by multiple NIH grants. The research in the department includes clinical pharmacology, pharmacokinetics, pharmacodynamics, and pharmacogenomics. Pharmaceutical Sciences occupies over 15,000 sq. ft. of contiguous state-of-the-art equipped laboratory and office space, and Pharmaceutical Services occupies over 18,000 square feet of space in the clinical areas of St. Jude. The department hosts weekly research workshops and journal clubs that are open to the entire institution and are widely attended by colleagues outside the department, in addition to multiple laboratory or Services specific meetings, webinars with national and international colleagues, and regular pharmacogenomics meetings.

Details on the rich St. Jude environment for clinical care and for clinical and basic research are available at www.stjude.org.

Pharmaceutical Department faculty, staff, and trainees work closely with each other; with our collaborators in other departments at St. Jude; and with colleagues around the world on basic translational, and clinical research projects and to provide outstanding pharmaceutical care to St. Jude patients.

Faculty:

William E. Evans. PharmD

Research in the Evans lab is focused on the pharmacogenomics of anticancer agents, with an emphasis on childhood acute lymphoblastic leukemia (ALL) (reviewed in Evans and Relling, *Nature* 2004; Pui and Evans, *NEJM* 2006; Paugh et al, *Clin Pharmacol Ther* 2011; Relling and Evans, *Nature* 2015). Several approaches are currently being used to identify genes and genome variations that are important determinants of the disposition and effects of antileukemic agents, including the use of genome wide approaches such as gene expression profiling (mRNA, microRNA) of leukemia cells, genome-wide SNP analyses (germline and somatic) and whole exome/genome sequencing of patient cohorts that have been uniformly treated and evaluated on prospective clinical trials at St. Jude Children's Research Hospital (reviewed in Evans




Figure 2. Post-doctoral fellows 2016-2017 **Back row:** Takaya Moriyama , Maxoxiang Qian, Ju Bao , Robert McCorkle, Charnise Goodings , Lee A. King, Jordan Beard, and Emily Finch **Front row:** Zachary Jones, Hui Zhang, Elixabet Lopez Lopez , Yiwei Liu, Juwina Wijaya, Yoshihiro Gochi, and Rebba Boswell-Casteel. Not pictured: Chengcheng Liu.




Figure 3: CASP1 causes glucocorticoid resistance via glucocorticoid receptor cleavage. Increased expression of inflammasome components CASP1 and NLRP3 via somatic hypomethylated promoter regions leads to glucocorticoid receptor cleavage by CASP1. Decreased levels of functional glucocorticoid receptor leads to blunted transcriptional response to glucocorticoids, glucocorticoid resistance in ALL cells and is associated with inferior treatment outcome (see Paugh et al, *Nature Genet* 2015).

and Relling, *Nature* 2004), or by our collaborators in the COG and in Europe (eg, Princess Maxima Center, Utrecht). Ongoing studies are investigating genes that the lab has linked with resistance to antileukemic agents (Figure 3) (Holleman et al, *NEJM* 2004; Lugthart et al, *Cancer Cell* 2005), and genes linked to the disposition (Kager et al, *JCI* 2005; Zaza, *Blood* 2005) or pharmacologic targets (Diouf et al, *JAMA* 2015; Paugh et al, *Nat Genet* 2015) of antileukemic agents as well as the influence of somatic and karyotypic abnormalities on genotype-phenotype concordance (Cheng, *Nature Genetics* 2005; Diouf et al, *Nature Med* 2011). Work in the lab is funded by a long-standing R01 from NCI (CA36401, W. Evans, PI), a project in the Center for Precision Medicine P50 Grant from NIGMS as part of the NIH-funded Pharmacogenetics Research Network (GM115279, M. Relling PI), by a Cancer Center Support grant from NCI (CA21765 C. Roberts, PI), and by ALSAC, the fundraising organization for St. Jude Children's Research Hospital. The lab comprises a number of post-doctoral fellows, staff scientists, research technologists, bioinformaticists, computational scientists and students, working with collaborators at St. Jude (including Mary Relling, Ching-Hon Pui, Charles Mullighan, K. Roberts, Hiroto Inaba, Kirsten Ness and Jun Yang as major collaborators, plus additional physicians, clinical pharmacists, research nurses and other staff at St. Jude), and with collaborators at other institutions in the US (HudsonAlpha, University of Chicago) and Europe (Erasmus University, Princess Maxima Center). The lab's overall goals are to elucidate genomic determinants of toxicity and efficacy of anticancer agents and translate this knowledge into new diagnostics and treatment strategies to optimize the therapy of ALL (Relling and Evans, *Nature* 2015; Dunnenberger et al, *Ann Rev Pharmacol Tox* 2015).

William Greene, PharmD

I joined Pharmaceutical Services as Chief Pharmaceutical Officer in August 2007. I have had a long career as a clinical pharmacy practitioner and leader in development of drug policy in hospital-based practice. My interests have been diverse and are summed up in the goal of developing structures, personnel, policy and practice to accomplish the best possible system to assure optimal outcomes of pharmacotherapy. My interests in Infectious Diseases, Pharmacokinetics, Performance Improvement and Medication Safety continue.


As the senior leader of Pharmaceutical Services, it is my goal to assure the best possible design and function of pharmacy services to assure that we achieve the desired outcomes of drug therapy for St. Jude patients. To this end, Pharmaceutical Services collaborates closely with other disciplines in providing patient care, and with clinicians and scientists in translational and clinical research, and employs the principles of continuous process improvement in ongoing refinement/improvement of patient-related services. Clinical research in Pharmaceutical Services has focuses on collaboration in applying pharmacokinetic, pharmacogenetic, and therapeutic drug monitoring principles to patient care, and in improving the safety of medication use. I currently retain a faculty appointment with the University of Tennessee College of Pharmacy (Professor, Affiliated), and am active in national and state professional organizations (immediate past member of the Board of Directors of Tennessee Pharmacists Association).

James M. Hoffman, Pharm

I joined the Pharmaceutical Department in 2004, and the St. Jude Faculty in 2011. My career has focused on evaluating and improving complex medication use systems, and I currently provide leadership to evaluate and improve a range of patient care processes through my role as the hospital's Chief Patient Safety Officer. I am also dedicated to postgraduate training by directing specialized residency program in Medication-Use Safety. My research is focused on patient safety

event detection, patient safety culture, and clinical decision support. Our work on patient safety event detection and reporting systems is built on our department's leadership to develop and implement St. Jude's novel electronic event reporting system software (EERS).

EERS is used to report all patient safety events at St. Jude, and this system has resulted in a 20% increase in event reporting. Because a healthy patient safety culture is essential to safe care, we have focused on assessing patient safety culture at St. Jude and devised new tools to measure specific aspects of safety culture in the hospital setting (Petschonek S et al *J Patient Saf* 2014 and Burlison JD et al *J Patient Saf* 2014). I also lead a variety of efforts to expand and improve the use of clinical decision support (CDS) in the electronic health record (EHR) Through the PG4KDS protocol, St. Jude is a leader in incorporating pharmacogenetic data and associated CDS into the EHR (Bell et al, *JAMIA*, 2013) (Figure 4), and I have contributed to this protocol as an investigator since its inception. I have also been actively engaged in the Clinical Pharmacogenetic Implementation Consortium (CPIC) since its inception, and I co-lead the CPIC Informatics Working Group. CPIC has devised vendor agnostic implementation resources which are available for each guideline (Hoffman et al. *JAMIA*, 2016). CPIC also recently lead a consensus process to standardize pharmacogenetic terms, which is being widely adopted and will help facilitate sharing pharmacogenetic results across disparate clinical information systems. (Caudle et al. *Genet Med*. 2016)




Mary V. Relling, PharmD

I have been a faculty member in the Pharmaceutical Department at St. Jude since 1988. Since then, the majority of my efforts have been directed to translational research in childhood acute lymphoblastic leukemia (ALL), although I have also maintained clinical involvement at St. Jude and in the Children's Oncology Group (COG). The clinical problems faced by children with ALL drive my research. Much of the work of my laboratory focuses on finding the genetic basis of why patients and their tumor cells differ from one another. I co-lead the Center for Precision Medicine in Leukemia (CPML), a

multidisciplinary research group (<http://www.pgrn.org/precision-medicine-in-leukemia.html>). We also study how nongenetic factors (e.g., diet and drug interactions, kidney and liver function, and age) affect how patients differ from each other in response to medications.

The ALL phenotypes we focus on most include relapse, glucocorticoid induced osteonecrosis (Figure 5) and asparaginase immunogenicity and pharmacodynamics. Our laboratory has a heavy reliance on computational approaches, as we use genome-wide tools to interrogate genetic variability.

We also use chemical analyses (e.g. HPLC, LC/MS) to study medication pharmacokinetics, cell culture models, molecular biologic techniques, murine models, and analysis of clinical outcomes and phenotypes. In 2011, we opened a clinical protocol, PG4KDS, with the goal of using array-based clinical genotyping to implement preemptive pharmacogenetic tests into clinical care for St. Jude patients (Dunnenberger et al 2014, Hoffman et al 2014). We collaborate with many investigators within the department, throughout St. Jude, within the COG, and within the Pharmacogenomics Research Network (PGRN).



Erin G. Schuetz, PhD

I joined the St. Jude Pharmaceutical Sciences Department in 1993. My lab studies cytochromes P450 (CYP) and other enzymes that metabolize many of the drugs administered to St. Jude patients. The lab identifies genetic determinants explaining variation in hepatic and intestinal CYP and AOX activities and, hence, variation in drug efficacy, toxicity and, ultimately, therapeutic outcome. The lab strategically uses both the candidate gene approach and exploits network and pathway analysis tools to illuminate the genetic variation in novel candidate genes affecting the CYP genetic network. The liver system biology/network approach has identified the node genes that, when individually perturbed, co-regulate many genes in the CYP network. My lab then uses deep resequencing of these novel candidate genes, and allelic expression imbalance analysis, to identify the functional and regulatory variants responsible for altering CYP activity and driving changes in the CYP expression network. Standard molecular, cellular and biochemical studies are then used to determine the functional consequence of these variants. Retrospective association studies are performed to determine

if functional variants in candidate genes translate to clinical differences in CYP mediated drug clearance.

Most recently our studies have focused on studying the impact of Vitamin D3 (VD3) sufficiency versus insufficiency on survival and chemotherapeutic efficacy and toxicity in a mouse model of acute lymphoblastic leukemia with the BCR-ABL fusion gene. These studies were prompted by the fact that a significant percentage of the pediatric population is VD3 deficient or insufficient, and that VD3 levels are further eroded during therapy because anti-chemotherapeutic regimens decrease the levels of the biologically active form of vitamin D3. Hence a major long-term consequence is a loss of bone mineral density in these pediatric patients during their peak bone building years. As a result, clinical trials have been initiated to determine whether vitamin D supplementation can correct VD3 insufficiency and improve bone density in children treated for leukemia. However, there was also a concern that vitamin D supplementation might cause drug interactions with medications metabolized by some drug metabolizing enzymes and drug transporters because the expression of some of them is regulated by VD3. Our results found that VD3 supplementation had no effect on the pharmacokinetics of glucocorticoids. However, because our results demonstrated a significant effect of VD3 on survival of mice from the BCR-ABL+ leukemia, and that the combination of VD3 and glucocorticoid therapy may prove beneficial in treating BCR-ABL+ leukemia, efforts are underway to determine the mechanisms by which VD3 mediates these effects.

John D. Schuetz, PhD

A member of the Pharmaceutical Sciences Department since December 1992, my laboratory focuses on understanding the contribution of ABC transporters to pathological processes and pharmacological response using cell culture model systems as well as gene knockout models (e.g., reviewed *Ann Rev Pharm Tox*, 2006 and 2013). Using these model systems, we have, through collaborative effort with other SJCRH investigators identified one ABC transporter as an important stem cell marker (Zhou et al, *Nat Med*, 2001, Zhou et al, *PNAS*, 2002) that has a prominent role in hematopoietic cell Survival under hypoxia (Krishnamurthy et al, *J Biol Chem*, 2004). We extended these studies to establish a knockout mouse which revealed for the first time that the ABC transporter (ABCC4/Mrp4) was important in protecting the brain from penetration of chemotherapeutic agents (Leggas et al, *Mol Cell Biol*, 2004). One could infer from these findings that the therapeutic efficacy of CNS-directed drugs that are Mrp4 substrates may be improved by developing Mrp4 inhibitors. The ABCC4/Mrp4 transporter was first functionally defined by my laboratory (Schuetz et al, *Nat Med*, 1999) and more recently was demonstrated to protect hematopoietic cells from injury due to the widely used immunosuppressive and cancer chemotherapeutic agent 6-mercaptopurine. This finding allowed us through collaborative efforts within the department (Evans, Relling, E. Schuetz) to identify a defective ABCC4 allele that was prevalent in the Asian population, thus providing an explanation for the anecdotal reports of enhanced sensitivity to the toxic hematopoietic side-effects of 6 mercaptopurine in this population (Krishnamurthy et al, *Cancer Res*, 2008). Further studies suggest ABCC4 has a strong role CFTR (L, et al, *Cell*, 2007) and also in modulating platelet aggregation as well as response to anti-platelet drugs (Cheepala, Pitre, et al, *Blood* 2015). Other studies have focused on a mitochondrial and plasma membrane ABC transporter we first characterized (Krishnamurthy et al, *Nature*, 2006; Fukuda et al, *J Biol Chem*, 2011) that protects cells from oxidative stress (Lynch et al, *Cancer Res*, 2009) and appears to have a unique role in regulating other survival responses. Because over a third of ABC transporters contribute to disease processes, our goal has been to understand the role of these genes in pathological conditions, such as our recently described roles for the bile acid transporter, *Abcb11*, in protecting against neonatal respiratory distress (Zhang et al, *Nat Commun*, 2015) and the ABCB6 transporter in modifying the severity of porphyria caused by defects in heme biosynthesis (Fukuda et al, *Nat Comm*, 2016). From this perspective, we have also been elucidating

how select ABC transporters contribute to cancer (medulloblastoma) (Morfouace et al, *Cancer Res.* 2105) and therapeutic response.

Clinton F. Stewart, PharmD

I joined the Pharmaceutical Department at St. Jude in 1991, and since then have focused my research efforts in developmental therapeutics for children with solid malignancies and central nervous system tumors. In the clinic, my research involves the application of state of the art pharmacokinetic (individual and population), pharmacogenetic, and pharmacodynamic approaches to understanding

the variability in drug disposition in children with cancer. Little is known about the disposition of anti-cancer agents in infants and young children less than 3 years of age, which often leads to increased risk of morbidity, poor tumor control, and increased incidence of late effects. Thus, we have embarked on a comprehensive series of pharmacokinetic, pharmacogenetic, and

pharmacodynamic studies to understand how

developmental changes in infants and young children affect the disposition and toxicities of anticancer drugs used in the treatment of infants with malignant brain tumors. Our long-term goal is to determine rational dosing regimens for infants and young children by better understanding the developmental pharmacology of anti-cancer drugs and to apply these regimens to therapy for other childhood malignancies and chronic medical conditions. In addition to the studies we perform at St. Jude, my lab collaborates with investigators within the Pediatric Brain Tumor Consortium and the Children's Oncology Group. Our work in the laboratory is guided by addressing clinically relevant problems encountered in the therapy of children with solid malignancies (e.g., effect of antiangiogenic drugs on cytotoxic drug penetration) or brain tumors (e.g., CNS drug penetration in brain tumors). The studies in the lab are designed to either yield data that can be translated into the design of improved clinical trials or to answer questions generated in the clinic. For example, the treatment of children with primary central nervous system (CNS) tumors continues to be a challenge despite recent advances in technology and diagnostics. A variety of issues unique to




Figure 6. Schematic overview of our approach to using Pharmacokinetic modeling and simulation in the identification of new anticancer drugs for treatment of pediatric CNS tumors.

pediatric CNS tumors impede development and clinical success of novel therapies and for this reason safe and effective treatments remain elusive. The preclinical approach we use (Figure 6) employs tumor subgroup-specific models of pediatric CNS tumors, cerebral microdialysis sampling of tumor extracellular fluid (tECF), and pharmacokinetic modeling and simulation to overcome challenges that currently hinder researchers in this field.

Jun I. Yang, PhD

I joined the St. Jude faculty in 2010 and I am currently an Associate Member in Pharmaceutical Sciences Department. The research focus of my group is pharmacogenomics of treatment outcomes (e.g. relapse) and toxicity in children with childhood acute lymphoblastic leukemia (ALL). Primarily taking a genome-wide approach, we identify genetic variations that contribute to interpatient variability in response to ALL therapy. By doing so, the goals of our research are to elucidate biological pathways dictating response to antileukemic drugs, to identify genetic predictors for drug resistance which can be utilized for treatment individualization, and to develop novel therapeutic agents to overcome drug resistance. Because genetic factors in both host and tumor genome can affect drug response, my lab has focused on characterization of inherited (germline) and acquired (somatic) genetic factors that are associated with treatment response in childhood ALL. We have led the first genome-wide association study to identify germline genetic variations associated with minimal residual disease in response to remission induction therapy in children with ALL (Yang et al, *JAMA*, 2009) and the first genome-wide interrogation of copy number alterations related to ALL relapse (Yang et al, *Blood*, 2008). We are particularly interested in the genetic basis for racial/ethnic differences in ALL treatment outcomes and disease susceptibility, e.g. we recently performed genome-wide studies to characterize ancestry-related genetic variants that (Perez-Andreu et al, *Nat Genet* 2013, *J Clin Oncol* 2012, *J Natl Cancer Inst* 2013) contribute to higher risk of relapse in Hispanic children with ALL (Yang et al, *Nat Genet*, 2011). We are also interested in pharmacogenetics of treatment toxicity, especially thiopurine-related myelosuppression (*J Clin Oncol* 2015, *Nat Genet* 2016). Our group is part of the NIH Pharmacogenomics Research Network (PGRN) and the Center for Precision Medicine for Leukemia (CPML).

Daniel Savic, PhD

I joined the Pharmaceutical Sciences Department at St. Jude Children's Research Hospital in August of 2016. My broad research interest involves deciphering the intricate, molecular processes that orchestrate the spatial and temporal regulation of genes, and how alterations to this regulatory logic contribute to disease. Prior to my faculty appointment at St. Jude, I was a member of the Encyclopedia of DNA Elements (ENCODE) consortium, a large, multi-center, collaborative effort that aims to functionally annotate the human genome. To better understand genome structure and function, I applied a variety of functional genomic techniques and next-generation reporter assays (Savic et al. *Genome Research* 2015, Savic et al. *Genome Medicine* 2016, review in Engel et al. *Semin Cell Dev Biol* 2016), and further engineered novel ChIP-seq based technologies that expand the utility (Savic et al. *Epigenetics and Chromatin* 2013) and enhance the capacity (Savic et al. *Genome Research* 2015) of the ChIP-seq functional genomic assay.

My laboratory at St. Jude focuses on the pharmacogenomics of treatment in pediatric acute lymphoblastic leukemia (ALL) in order to better understand the molecular underpinnings of anticancer drug resistance and disease relapse. Our group aims to address a critical question in ALL pharmacogenomics: how does the non-coding, regulatory genome impact drug response and disease

relapse? To address this question, the main goals of our concerted research effort are: (1) to systematically identify “drug-response CREs” (drCREs), (2) to define the molecular mechanisms linking drCREs to drug resistance, (3) to connect non-coding, DNA sequence variation with differences in interpatient drug sensitivity, and (4) to assess epigenomic heterogeneity and clonal evolution in leukemic blasts.

Liqin Zhu, PhD

I joined Pharmaceutical Sciences Department as a Research Associate in 2016. My research program focuses on understanding the metastasis mechanisms of pediatric hepatoblastoma (HB) and hepatocellular carcinoma (HCC) to facilitate the development of effective and personalized therapy for the aggressive forms of liver cancer. We use three main approaches to study HB and HCC metastasis, including: (1) using *in vitro* 3D liver stem cell culture to grow liver cancer spheroids from mouse and human tumors and characterize the mechanisms contributing to their tumorigenicity; (2) generating cancer spheroid-driven orthotopic transplantation mouse models for liver cancer and characterize the *in vivo* mechanisms driving liver cancer metastasis; (3) conducting liver cancer spheroid-based drug screen to identify new treatment for metastatic HB and HCC. Our preliminary study has demonstrated the ability of liver cancer spheroids to drive highly invasive and metastatic tumors *in vivo*. The liver cancer spheroid-driven secondary tumors faithfully recapitulate human recurrent and metastatic liver cancers at both histologic and molecular levels, which has provided us a novel preclinical model to identify potential new therapies for high risk liver cancers that are otherwise refractory to standard-of-care treatments.

Pharmaceutical Services

Pharmaceutical Services is led by Dr. William Greene and is staffed by pharmacists, pharmacy technicians, research and administrative staff, and faculty, (see Organization Chart at end) all dedicated to helping patients. St. Jude Pharmaceutical Services focuses on providing the best pharmaceutical care required for each child at SJCRH while supporting a collective research endeavor. Our personnel, working with other caregivers in a cutting edge collaborative environment assure the best possible outcomes of drug therapy. Nearly 120 pharmacists, technicians, and other support personnel are involved in the care of patients and support of clinical research at St. Jude, helping to fulfill our organizational mission to “advance cures, and means of prevention, for pediatric catastrophic diseases through research and treatment.”




Figure 7. Just for the *CYP2D6* gene, 56 different diplotypes have been observed in the first 499 patients enrolled on the St. Jude clinical protocol, PG4KDS. Each diplotype is translated into a phenotype; high-risk phenotypes drive drug prescribing (Hicks et al 2012).

Pharmaceutical Services addresses St. Jude patients across the continuum of care – providing services while they are inpatients, in the outpatient clinic, and while in domiciliary facilities or at home. Inpatient services include Clinical Pharmacist collaboration in management of patients of all major clinical patient care groups, including Leukemia/Lymphoma, Solid Tumor, Neuro-Oncology, Bone Marrow Transplant, Hematology, and HIV services. After discharge from the hospital, these patients are seen in outpatient clinics located on campus where pharmacists are directly involved with provider teams. In these settings, pharmacists collaborate in the care of these patients, including the ordering of medications and laboratory tests, the development of clinical treatment protocols, provision of drug therapy and nutritional support consults, and assessment and management of the long-term effects of medication therapy. An on-site infusion center pharmacy provides medications for outpatients, and is fully staffed by pharmacists. On average, there are approximately 400 patient clinic visits per day, with 103 infusion center encounters, leading to the dispensing of 802 prescriptions or doses per day. An inpatient census of approximately 58 patients per day requires more than 2,150 dispensed doses per day. Nutrition support, pharmacokinetic, and pharmacogenetic consults, (Figure 7) and routine medication reconciliation at discharge require direct pharmacist involvement in patient care. Patients requiring intravenous therapy while outside the hospital are managed through provision of therapy by the St. Jude Specialty/Home Infusion Pharmacy. This service, initiated in early spring of 2011, was recognized by a Joint Commission surveyor as exhibiting several “best practices” and having no recommendations for improvement during surveys in August of 2011 and November 2012. This service is now providing more than 340 doses per day, and is caring for all St. Jude patients in the immediate service region.

At St. Jude, we provide the very best professional environment for pharmacists (Figure 8) – one that supports growth and achievement of professional goals. Clinical Staff Pharmacists work from both centralized and decentralized settings to collaborate with clinical providers in patient care. Clinical Research



Figure 8. Pharmacists are integral members of each of St. Jude’s clinical services.

Pharmacists, Informatics Pharmacists, and pharmacist leaders in medication outcomes and medication safety work to assure optimal system support and design to facilitate the best outcomes of patient care and clinical research. Certified Pharmacy Technicians collaborate with pharmacists to assure excellence in operational functions. A technician career ladder has been developed, and pharmacist developmental pathways provide internal opportunities for professional growth.

Professional society involvement is encouraged, and resources are dedicated to enhance professional growth. St. Jude pharmacists play an active role in the Children’s Oncology Group, American College of Clinical Pharmacy, American Society of Health-System Pharmacy, and many other professional organizations.

St. Jude Pharmaceutical Services also collaborates closely with various colleges of pharmacy in providing experiential education to pharmacy students. The department is formally affiliated with

the University of Tennessee (UT) College of Pharmacy, but also works with students from other colleges as they request the opportunity. Members of the department hold affiliated faculty appointments with the UT College of Pharmacy. St. Jude pharmacy personnel provide approximately 60 student-months of experience during an academic year and 40 contact hours of classroom training for UT pharmacy students.

Pharmacists are integrated into each of the major clinical services at St. Jude and state-of-the-art distribution and computer support systems assure efficient, effective delivery and use of medications. Pharmacy Information Systems is intimately involved in the maintenance and refinement of a complete electronic medical record with computerized prescriber order entry and clinical decision support. These same personnel lead efforts to identify and implement the best technology to ensure optimal and safe patient outcomes.

Pharmacy Specialty Residencies

Trainees at St. Jude are supported by an institutional Office of Academic Programs, whose goal is to assist our investigators and professional staff to improve the quality of experiences, training, benefits, and support for our undergraduate, graduate, professional and postdoctoral trainees.

Over 300 post-doctoral trainees (post-Ph.D, M.D, and Pharm.D.) are at St. Jude, among whom are our PGY2 pharmacy specialty residents. Our PGY2 residencies in Pediatric Oncology, Medication Use Safety, and in Pharmacogenomics are accredited by the American Society of Health System Pharmacists (ASHP). Further details are available on St. Jude's website (www.stjude.org/pharmacyresidency).



Figure 9. St. Jude PGY2 residents 2016-2017 (left to right): Deni Tone, PharmD, PhD; Jennifer Hockings, PharmD, PhD; Dagny Ulrich, PharmD, PhD; Nicholas Lockhart, PharmD.

Pharmacokinetics Shared Resource

The Pharmacokinetics Shared Resource is part of the NCI-designated Cancer Center, is housed within Pharmaceutical Sciences laboratory space, is directed by Dr. Mary Relling, and provides centralized high-quality, competitively funded, peer-reviewed pharmacokinetic/pharmacodynamics research in both clinical and pre-clinical models at the St. Jude Cancer Center.

Our objectives are to facilitate:

Proper pharmacokinetic study design and implementation

Efficient and proper collection of biological samples for clinical pharmacokinetic and pharmacodynamic studies

Implementation and quality control of sensitive and specific analyses of those samples for anticancer drugs, their metabolites, or other relevant pharmacologic indices

The biomedical modeling of pharmacokinetic and pharmacodynamic data

Services include:

Protocol implementation (development of standard physician orders; building computerized laboratory tests; refining sampling and processing procedures)

Research sample acquisition (centralized receiving, initial processing, storage, and distribution)

Analytical assay implementation and ongoing quality control, biomedical modeling, study design and optimal sampling

Clinical Pharmacokinetics Laboratory

The Clinical Pharmacokinetics Laboratory (CPK lab), located in the Pharmaceutical Department supports St. Jude's mission by providing state of the art therapeutic drug monitoring and pharmacogenetic testing that is interpreted by clinical pharmacists to assure optimal drug dosing. It is directed by Dr. Alejandro Molinelli with translational support from Dr. Kristine Crews.

The Clinical Pharmacokinetics Laboratory is certified as a high complexity laboratory by CLIA and is accredited by the College of American Pathologists. Our staff consists of licensed medical laboratory scientists. Every year the laboratory will process and analyze approximately 8000 clinical specimens and send-out another 300 to reference laboratories. The laboratory's in-house test menu includes multiple high-complexity assays ranging from therapeutic drug determinations (e.g. immunosuppressant, antifungal drugs) to glomerular filtration rate estimation using ^{99m}Tc - DTPA. Some of our resources include random access immunochemistry analyzers (e.g. Abbott Architect) and analytical instrumentation (e.g. LC-MS/MS, GC/MS, HPLC). Most of our instruments have bidirectional interfaces with the Cerner Millennium clinical informatics system. The laboratory also handles pharmacogenetic testing for the hospital offering genotyping results that are always accompanied by consults prepared by the clinical pharmacists or residents.

The laboratory staff and pharmacists at St. Jude work closely to provide results in a timely manner. Once a test result is obtained the laboratory scientists alert the pharmacist, who in turn prepares a clinical consult. This close integration of care assures that our patients receive the best treatment while minimizing adverse effects from the drugs. The laboratory staff is also involved in clinical translational science projects, for which tests developed in the research laboratories are validated and incorporated into the CPK lab test menu as needed.

In addition to the samples for clinical testing, the CPK laboratory staff members also process thousands of patient research specimens a year, in support of various St. Jude research protocols, for the Pharmacokinetics Shared Resource.

Pharmaceutical Department Publications 2015-2016



Aziz A, Kawamoto K, Eilbeck K, Williams MS, Freimuth RR, Hoffman MA, Rasmussen LV, Overby CL, Shirts BH, Hoffman JM, Welch BM. The genomic CDS sandbox: an assessment among domain experts. *J Biomed Inform.* 2016 (60): 84-94 (PMCID: PMC4948866)

Archer NP, Perez-Andreu V, Scheurer ME, Rabin KR, Peckham-Gregory EC, Plon SE, Zabriskie RC, De Alarcon PA, Fernandez KS, Najera CR, Yang JJ, Antillon-Klussmann F, Lupo PJ. Family-based exome wide assessment of maternal genetic effects on susceptibility to childhood B-cell acute lymphoblastic leukemia in hispanics. *Cancer.* 2016 Aug 16. (PMCID: PMC5115939)

Bailey KA, Savic D, Zielinski M, Park SY, Wang L, Witkowski P, Brady M, Hara M, Bell GI, Nobrega MA. Evidence of non-pancreatic beta cell-dependent roles of Tcf7l2 in the regulation of glucose metabolism in mice. *Hum Mol Genet* 24(6):1646-1654, 2015. (PMCID: PMC4381752)

Bhatia S, Landier W, Hageman L, Chen Y, Kim H, Sun CL, Kornegay N, Evans WE, Angiolillo AL, Bostrom B, Casillas J, Lew G, Maloney KW, Mascarenhas L, Ritchey AK, Termuhlen AM, Carroll WL, Wong FL, Relling MV. Systemic Exposure to Thiopurines and Risk of Relapse in Children with Acute Lymphoblastic Leukemia: A Children's Oncology Group Study. *JAMA Oncol.* 2015 1(3):287-95. (PMCID: PMC4561178)

Bhojwani D, Yang JJ, Pui C-H. Biology of Childhood Acute Lymphoblastic Leukemia. *Pediatr Clin North Am.* 2015 Feb;62(1):47-60. (PMCID: PMC4250840)

Bi W, Kang G, Zhao Y, Cui Y, Yan S, Li Y, Cheng C, Pounds SB, Borowitz MJ, Relling MV, Yang JJ, Liu Z, Pui CH, Hunger SP, Hartford CM, Leung W, Zhang JF. SVSI: Fast and Powerful Set-Valued System Identification Approach to Identifying Rare Variants in Sequencing Studies for Ordered Categorical Traits. *Ann Hum Genet.* 2015 79(4):294-309. (PMCID: PMC4474746)

Boer JM, Marchante JR, Evans WE, Horstmann MA, Escherich G, Pieters R, Den Boer ML. BCR-ABL1 like cases in pediatric acute lymphoblastic leukemia: a comparison between DCOG/Erasmus MC and COG/Erasmus MC and COG/St. Jude signatures. *Haematologica.* 2015 Sep;100(9):e354-7. doi: 10.3324/haematol.2015.124941. Epub 2015 Jun 4. (PMCID: PMC4800707)

Burlison JD, Quillivan RR, Scott SD, Johnson S, Hoffman JM. The effects of the second victim phenomenon on work-related outcomes: connecting self-reported caregiver distress to turnover intentions and absenteeism. *J Patient Saf.* 2016 Nov 2. [Epub ahead of print]

Burlison JD, Quillivan RR, Kath LM, Zhou Y, Courtney SC, Cheng C, Hoffman JM. A multilevel analysis of U.S. hospital patient safety culture relationships with perceptions of voluntary event reporting. *J Patient Saf.* 2016 Nov 3. [Epub ahead of print]

Burger H, Den Dekker AT, Segeletz S, Boersma AWM, De Bruijn P, Debiec-Rychter M, Taguchi T, Sleijfer S, Sparreboom A, Mathijssen RH, Wiemer EAC. Intracellular imatinib levels are primarily determined by lysosomal sequestration. *Br J Pharmacol* 2015 88(3): 477-87 PMID: 26108972

Caudle KE, Dunnenberger HM, Freimuth RR, Peterson JF, Burlison JD, Whirl-Carrillo M, Scott SA, Rehm HL, Williams MS, Klein TE, Relling MV, Hoffman JM. Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC). *Genet Med*. 2016 Jul 21. [Epub ahead of print] *PMID: 27441996*

Caudle KE, Gammal RS, Whirl-Carrillo M, Hoffman JM, Relling MV, Klein TE. Evidence and resources to implement pharmacogenetic knowledge for precision medicine. *Am J Health Syst Pharm*. 2016 Dec 1;73(23):1977-1985. (*PMCID:PMC5117674*)

Chaudhry A, Prasad B, Shirasaka Y, Fohner A, Finkelstein D, Fan Y, Wang S, Wu S, Aklillu E, Sim S, Thummel KE and Schuetz EG. The CYP2C19 intron 2 branch point SNP is the ancestral polymorphism contributing to the poor metabolizer phenotype in livers with CYP2C19*35 and CYP2C19*2 alleles. *Drug Metab Dispos*. 2015 Aug; 43(8):1226-35. (*PMCID: PMC4518065*)

*Cheepala SB, *Pitre A, Fukuda Y, Takenaka K, Zhang Y, Wang Y, Frase S, Pestina T, Gartner TK, Jackson C, Schuetz JD. The ABCG4 membrane transporter modulates platelet aggregation. *Blood*. 2015 Nov 12;126(20):2307-19 (*PMCID: PMC4643005*) *co-first authorship

Chhibber A, French CE, Yee SW, Gamazon ER, Theusch E, Qin X, Webb A, Papp AC, Wang A, Simmons CQ, Konkashbaev A, Chaudhry AS, Mitchel K, Stryke D, Ferrin TE, Weiss ST, Kroetz DL, Sadee W, Nickerson DA, Krauss RM, George AL, Schuetz EG, Medina MW, Cox NJ, Scherer SE, Giacomini KM, Brenner SE. Transcriptomic variation of pharmacogenes in multiple human tissues and lymphoblastoid cell lines. *Pharmacogenomics J*. 2016 Feb 9 (epub ahead of print) (*PMCID: PMC4980276*)

Daryani, V. M., Patel, Y. T., Tagen, M., Turner, D. C., Carcaboso, A. M., Atkinson, J. M., Gajjar, A., Gilbertson, R. J., Wright, K. D. and Stewart, C. F. Translational Pharmacokinetic-Pharmacodynamic Modeling and Simulation: Optimizing 5-Fluorouracil Dosing in Children With Pediatric Ependymoma. *CPT Pharmacometrics Syst Pharmacol*. Apr 14, 2016. (*PMCID: PMC4834132*)

De Graan AJ, Sparreboom A, De Bruijn P, De Jonge E, Van der Holt B, Wiemer EAC, Verweij J, Mathijssen RH, Van Schaik RH. 4 β -Hydroxycholesterol as an endogenous CYP3A marker in cancer patients treated with taxanes. *Br J Pharmacol* 2015 80(3): 560-8 (*PMCID: PMC4574840*)

DeWire M, Fouladi M, Turner DC, Wetmore C, Hawkins C, Jacobs C, Yuan Y, Liu D, Goldman S, Fisher P, Rytting M, Bouffet E, Kahkoo Y, Hwang E, Foreman N, Stewart CF, Gilbert MR, Gilbertson R, Gajjar A. An open-label, two-stage, Phase II study of bevacizumab and lapatinib in children with recurrent or refractory ependymoma: a Collaborative Ependymoma Network Study (CERN). *J Neurooncol* 2015 123(1):85-91. (*PMCID: PMC4992988*)

Diouf B, Crews KR, Lew G, Pei D, Cheng C, Bao J, Zheng JJ, Yang W, Fan Y, Wheeler HE, Wing C, Delaney SM, Komatsu M, Paugh SW, McCorkle JR, Li X, Winick NJ, Carroll WL, Loh ML, Hunger SP, Devidas M, Pui C-H, Dolan ME, Relling MV, Evans WE. Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia. *JAMA* 2015 313(8): 815-23 (*PMCID: PMC4377066*)

Diouf B, Crews KR, Evans WE. Vincristine pharmacogenomics: 'Winner's curse' or a different phenotype? *Pharmacogenet Genomics*. 2016 Feb. (*PMID 26704670*)

Drenberg CD, Paugh SW, Pounds S, Shi L, Orwick SJ, Li L, Hu S, Gibson A, Ribeiro R, Rubnitz J, Sparreboom A, Baker SD. Inherited variation in OATP1B1 is associated with treatment outcome in acute myeloid leukemia. *Clin Pharmacol Ther*, 2016 Jun;99(6): 651-60 (PMCID: PMC4898266)

Drenberg C, Hu S, Li L, Buelow D, Orwick S, Gibson A, Schuetz JD, Sparreboom A, and Baker S. ABCC4 is a Determinant of Cytarabine-Induced Cytotoxicity and Myelosuppression. *Clin Transl Sci*. 2016 Feb;9(1):51-9. (PMCID: PMC4905720)

Dunnenberger HM, Crews KR, Hoffman JM, Caudle KE, Broeckel U, Howard SC, Hunkler RJ, Klein TE, Evans WE, Relling MV. Preemptive Clinical Pharmacogenetics Implementation: Current Programs in Five United States Medical Centers. *Annu Rev Pharmacol Toxicol*. 2015;55:89-106 (PMCID: PMC4607278)

Edelmann, M.N., V.M. Daryani, M.W. Bishop, W. Liu, T.M. Brinkman, C.F. Stewart, D.A. Mulrooney, C. Kimberg, K.K. Ness, Y.T. Cheung, D.K. Srivastava, L.L. Robison, M.M. Hudson, and K.R. Krull. Neurocognitive and Patient-Reported Outcomes in Adult Survivors of Childhood Osteosarcoma. *JAMA Oncol*, 2015: p. 1-8. (PMCID:PMC4752424)

Engel KL, Mackiewicz M, Hardigan AA, Myers RM, Savic D.* Decoding transcriptional enhancers: Evolution from annotation to functional interpretation. *Semin Cell Dev Biol* 57:40-50, 2016. (PMCID:PMC5018832) (*corresponding author)

Fernandez CA, Smith C, Karol SE, Ramsey LB, Liu C, Pui CH, Jeha S, Evans WE, Finkelman FD, Relling MV. Effect of premedications in a murine model of asparaginase hypersensitivity. *J Pharmacol Exp Ther*. 2015 Mar;352(3):541-51 (PMCID:PMC4352598)

Fernandez CA, Smith C, Yang W, Mullighan CG, Qu C, Larsen E, Bowman WP, Liu C, Ramsey LB, Chang TY, Karol SE, Loh ML, Raetz EA, Winick N, Hunger SP, Carroll WL, Jeha S, Pui CH, Evans WE, Devidas M, and Relling MV. Genome-wide analysis links NFATC2 with asparaginase hypersensitivity. *Blood*. 2015 126(1):69-75. (PMCID: PMC4492197)

Fernandez CA, Smith C, Karol SE, Ramsey LB, Liu C, Pui CH, Jeha S, Evans WE, Finkelman FD, Relling MV. Effect of premedications in a murine model of asparaginase hypersensitivity. *J Pharmacol Exp Ther*. 2015 352(3):541-51 (PMCID: PMC4352598)

Fukuda Y, Cheong PL, Lynch J, Brighton C, Frase S, Kargas V, Rampersaud E, Wang Y, Sankaran VG, Yu B, Ney PA, Weiss MJ, Vogel P, Bond PJ, Ford RC, Trent RJ, Schuetz JD. The severity of hereditary porphyria is modulated by the porphyrin exporter and Lan antigen ABCB6. *Nat Commun*. 2016 Aug 10;7:12353. doi: 10.1038/ncomms12353. (PMCID: PMC4987512)

Gammal RS, Crews KR, Haidar CE, Hoffman JM, Baker DK, Barker PJ, Estep JH, Pei D, Broeckel U, Wang W, Weiss MJ, Relling MV, Hankins J. Pharmacogenetics for Safe Codeine Use in Sickle Cell Disease. *Pediatrics*. 2016 Jul;138(1). pii: e20153479. doi: 10.1542/peds.2015-3479. (PMCID:PMC4925073)

Gilbertson, R. J., Wright, K. D. and Stewart, C. F. Translational Pharmacokinetic-Pharmacodynamic Modeling and Simulation: Optimizing 5-Fluorouracil Dosing in Children With Pediatric Ependymoma. *CPT Pharmacometrics Syst Pharmacol*. Apr 14, 2016. (PMCID: PMC4834132)

Goldspiel BR; DeChristoforo R; Hoffman JM; Preventing chemotherapy errors: Updating guidelines to meet new challenges. *Am J Health Syst Pharm.* 2015 72 (8):668-669 *PMID:25825190*

PMC Journal In Process

Goldspiel B, Hoffman JM, Griffith NL, Goodin S, DeChristoforo R, Montello CM, Chase JL, Bartel S, Patel JT. ASHP Guidelines on Preventing Medication Errors with Chemotherapy and Biotherapy. *Am J Health Syst Pharm.* 2015 72 (8):e6-e35. *PMID:25825193 PMC Journal In Process*

Guo, J., J.O. Glass, M.B. McCarville, B.L. Shulkin, V.M. Daryani, C.F. Stewart, J. Wu, S. Mao, J.R. Dwek, L.M. Fayad, J.E. Madewell, F. Navid, N.C. Daw, and W.E. Reddick. Assessing vascular effects of adding bevacizumab to neoadjuvant chemotherapy in osteosarcoma using DCE-MRI. *Br J Cancer*, 2015. 113(9): p. 1282-8. (*PMCID:PMC4815789*)

Hall JL, Ryan JJ, Bray BE, Brown C, Lanfear D, Newby LK, Relling MV, Risch NJ, Roden DM, Shaw SY, Tchong JE, Tenenbaum J, Wang TN, Weintraub WS. Merging Electronic Health Record Data and Genomics for Cardiovascular Research: A Science Advisory From the American Heart Association. *Circ Cardiovasc Genet.* 2016 Mar 14. [Epub ahead of print] *PMID: 26976545 PMC Journal in Process*

Hartke PL, Vermeulen LC, Hoffman JM, Shah ND, Doloresco F, Suda KJ, Matusiak LM, Hunkler RJ, Schumock GT. Accuracy of annual prescription drug expenditure forecasts in AJHP. *Am J Health Syst Pharm.* Oct. 2015 72 (19):1642-1648. (*PMCID:PMC4576353*)

Hicks JK, Dunnenberger HM, Gumper KF, Haidar CE, Hoffman JM. Integrating pharmacogenomics into electronic health records with clinical decision support. *Am J Health Syst Pharm.* 2016 73 (23): 1967-1976. (*PMCID: PMC5117634*)

Hoffman LM, Fouladi M, Olson J, Daryani VM, Stewart CF, Wetmore C, Kocak M, Onar-Thomas A, Wagner L, Gururangan S, Packer RJ, Blaney SM, Gajjar A, Kun LE, Boyett JM, Gilbertson RJ. Phase I trial of weekly MK-0752 in children with refractory central nervous system malignancies: a pediatric brain tumor consortium study. *Childs Nervous System* 31:1283-1289, 2015 (*PMCID: PMC4681692*).

Hoffman JM, Dunnenberger HM, Kevin Hicks J, Caudle KE, Whirl Carrillo M, Freimuth RR, WilliamsMS, Klein TE, Peterson JF. Developing knowledge resources to support precision medicine: principles from the Clinical Pharmacogenetics Implementation Consortium (CPIC). *J Am Med Inform Assoc.* 2016 (23): 796-801. *PMID: 27026620 PMC Journal In Process*

Hungate EA, Vora SR, Gamazon ER, Moriyama T, Best T, Hular I, Lee Y, Evans TJ, Ellinghaus E, Stanulla M, Rudant J, Orsi L, Clavel J, Milne E, Scott RJ, Pui CH, Cox NJ, Loh ML, Yang JJ, Skol AD, Onel K. A variant at 9p21.3 functionally implicates CDKN2B in paediatric B-cell precursor acute lymphoblastic leukaemia aetiology. *Nat Commun.* 2016 Feb 12;7:10635. (*PMCID: PMC4754340*)

Jacus MO, Rahija R, Davis A, Throm SL, Stewart CF. An observational evaluation of mice during cerebral microdialysis procedures used in pediatric brain tumor research. *J Am Assoc Lab Anim Sci.* 2015 May;54(3):304-10. (*PMCID: PMC4460944*)

Jacus, M.O., V.M. Daryani, K.E. Harstead, Y.T. Patel, S.L. Throm, and C.F. Stewart. Pharmacokinetic Properties of Anticancer Agents for the Treatment of Central Nervous System Tumors: Update of the Literature. *Clin Pharmacokinet.* 2015 Aug 21. [Epub ahead of print] (*PMCID: PMC4761278*)

Kalman LV, Agúndez JA, Appell ML, Black JL, Bell GC, Boukouvala S, Bruckner C, Bruford E, Bruckner C, Caudle K, Coulthard S, Daly AK, Del Tredici AL, den Dunnen JT, Drozda K, Everts R, Flockhart D, Freimuth R, Gaedigk A, Hachad H, Hartshorne T, Ingelman-Sundberg M, Klein TE, Lauschke VM, Maglott DR, McLeod HL, McMillin GA, Meyer UA, Müller DJ, Nickerson DA, Oetting WS, Pacanowski M, Pratt VM, Relling MV, Roberts A, Rubinstein WS, Sangkuhl K, Schwab M, Scott SA, Sim SC, Thirumaran RK, Toji LH, Tyndale R, van Schaik RH, Whirl-Carrillo M, Yeo KJ, Zanger UM. Pharmacogenetic Allele Nomenclature: International Workgroup Recommendations for Test Result Reporting. *Clin Pharmacol Ther.* 2016 Feb;99(2): 172-85 (PMCID: PMC4724253)

Kang G, Liu W, Cheng C, Wilson CL, Neale G, Yang JJ, Ness KK, Robison LL, Hudson MM, Srivastava DK. Evaluation of a two-step iterative resampling procedure for internal validation of genome-wide association studies. *J Hum Genet.* 2015 Dec;60 (12):729-38. (Epub ahead of print) (PMID: 26377241, PMCID n/a)

Karol SE, Yang W, Van Driest SL, Chang TY, Kaste S, Bowton E, Basford M, Bastarache L, Roden DM, Denny JC, Larsen E, Winick N, Carroll WL, Cheng C, Pei D, Fernandez CA, Liu C, Smith C, Loh ML, Raetz EA, Hunger SP, Scheet P, Jeha S, Pui CH, Evans WE, Devidas M, Mattano LA Jr, Relling MV. Genetics of glucocorticoid-associated osteonecrosis in children with acute lymphoblastic leukemia. *Blood.* 2015 126(15): 1770-6. (PMCID: PMC4600016)

Karol SE, Mattano LA Jr, Yang W, Maloney KW, Smith C, Liu C, Ramsey LB, Fernandez CA, Chang TY, Neale G, Cheng C, Mardis E, Fulton R, Scheet P, San Lucas FA, Larsen EC, Loh ML, Raetz EA, Hunger SP, Devidas M, Relling MV. Genetic risk factors for the development of osteonecrosis in children under age 10 treated for acute lymphoblastic leukemia. *Blood.* 2016; 127(5): 558-64 (PMCID: PMC4742546)

Kaste SC, Pei D, Cheng C, Neel MD, Bowman WP, Ribeiro RC, Metzger ML, Bhojwani D, Inaba H, Campbell P, Rubnitz J, Jeha S, Sandlund JT, Downing J, Relling MV, Pui C-H, Howard SC. Utility of early screening magnetic resonance imaging for extensive hip osteonecrosis in pediatric patients treated with glucocorticoids. *J Clin Oncol.* 2015 33(6): 610-5 (PMCID: PMC4322260)

Kieran MW, Chi S, Goldman S, Onar-Thomas A, Poussaint TY, Vajapeyam S, Fahey F, Wu S, Turner DC, Stewart CF, Moses M, Packer RJ, Jakacki R, Banerjee A, Boyett JM, Fouladi M, Kun L. A phase I trial and PK study of cediranib (AZD2171), an orally bioavailable pan-VEGFR inhibitor, in children with recurrent or refractory primary CNS tumors. *Childs Nerv Syst.* 2015 Sep;31(9):1433-45 (PMCID: PMC4561207).

Kim MJ, Yu CY, Theusch E, Naidoo D, Stevens K, Kuang YL, Schuetz E, Chaudhry AS, Medina MW. SUGP1 is a novel regulator of cholesterol metabolism. *Hum Mol Genet.* 2016 Jul 15;25(14):3106-3116. (PMCID: PMC5181593)

Lamba JK, Pounds S, Cao X, Crews KR, Cogle CR, Bhise N, Raimondi SC, Downing JR, Baker SD, Ribeiro RC, Rubnitz JE. Clinical significance of in vivo cytarabine-induced gene expression signature in AML. *Leuk Lymphoma.* 2015 Oct 16:1-12. PMID: 26366682

Li B, Li H, Bai Y, Kirschner-Schwabe R, Yang JJ, Chen Y, Lu G, Tzoneva G, Ma X, Wu T, Li W, Lu H, Ding L, Liang H, Huang X, Yang M, Jin L, Kang H, Chen S, Du A, Shen S, Ding J, Chen H, Chen J, von Stackelberg A, Gu L, Zhang J, Ferrando A, Tang J, Wang S, Zhou BB. Negative feedback-defective

PRPS1 mutants drive thiopurine resistance in relapsed childhood ALL. *Nat Med.* 2015 Jun;21(6):563-71. (PMCID: PMC4670083)

Li-Harms X, Milasta S, Lynch J, Wright C, Joshi A, Iyengar R, Neale G, Wang X, Wang Y-D, Prolla T, Thompson JE, Opferman J, Green DR, Schuetz JD, Kundu, M. Mito-protective autophagy is impaired in erythroid cells of aged mtDNA-mutator mice. *Blood.* 2015 Jan 1;125(1):162-74. (PMCID:PMC4281825)

Liu C, Janke LJ, Kawedia JD, Ramsey LB, Cai X, Mattano LA Jr, Boyd KL, Funk AJ, Relling MV. Asparaginase Potentiates Glucocorticoid-Induced Osteonecrosis in a Mouse Model. *PLoS One.* 2016 Mar 11;11(3):e0151433. eCollection 2016 (PMCID:PMC4788417)

Liu C, Yang W, Devidas M, Cheng C, Pei D, Smith C, Carroll WL, Raetz EA, Bowman WP, Larsen EC, Maloney KW, Martin PL, Mattano LA Jr, Winick NJ, Mardis ER, Fulton RS, Bhojwani D, Howard SC, Jeha S, Pui CH, Hunger SP, Evans WE, Loh ML, Relling MV. Clinical and Genetic Risk Factors for Acute Pancreatitis in Patients with Acute Lymphoblastic Leukemia. *J Clin Oncol.* 2016 34(18): 2133-40 (PMCID:PMC4962704)

Liu C, Yang W, Pei D, Cheng C, Smith C, Landier W, Hageman L, Chen Y, Yang JJ, Crews KR, Kornegay N, Karol SE, Wong FL, Jeha S, Sandlund JT, Ribeiro RR, Rubnitz JE, Metzger ML, Pui CH, Evans WE, Bhatia S, Relling MV. A Genome-wide Approach Validates that Thiopurine Methyltransferase Activity is a Monogenic Pharmacogenomic Trait. *Clin Pharmacol Ther.* 2016 Aug 26. [Epub ahead of print] PMID: 27564568

Liu YF, Wang BY, Zhang WN, Huang JY, Li BS, Zhang M, Jiang L, Li JF, Wang MJ, Dai YJ, Zhang ZG, Wang Q, Kong J, Chen B, Zhu YM, Weng XQ, Shen ZX, Li JM, Wang J, Yan XJ, Li Y, Liang YM, Liu L, Chen XQ, Zhang WG, Yan JS, Hu JD, Shen SH, Chen J, Gu LJ, Pei D, Li Y, Wu G, Zhou X, Ren RB, Cheng C, Yang JJ, Wang KK, Wang SY, Zhang J, Mi JQ, Pui CH, Tang JY, Chen Z, Chen SJ. Genomic Profiling of Adult and Pediatric B-cell Acute Lymphoblastic Leukemia. *EBioMedicine.* 2016 Jun;8:173-83. (PMCID: PMC4919728)

Lu C, Zhang J, Nagahawatte P, Easton J, Lee S, Liu Z, Ding L, Wyczalkowski MA, Valentine M, Navid F, Mulder H, Tatevossian RG, Dalton J, Davenport J, Yin Z, Edmonson M, Rusch M, Wu G, Li Y, Parker M, Hedlund E, Shurtleff S, Raimondi S, Bhavin V, Donald Y, Mardis ER, Wilson RK, Evans WE, Ellison DW, Pounds S, Dyer M, Downing JR, Pappo A, Bahrami A. The Genomic Landscape of Childhood and Adolescent Melanoma. *J Invest Dermatol.* 2015 135(3): 816-23 (PMCID: PMC4340976)

Ma X, Edmonson M, Yergeau D, Muzny D, Hampton OA, Rusch M, Song G, Easton J, Harvey RC, Wheeler DA, Ma J, Doddapaneni H, Vadodaria B, Wu G, Nagahawatte P, Carroll WL, Chen I-M, Gastier Foster JM, Relling MV, Smith MA, Devidas M, Guidry Auvil JM, Downing JR, Loh ML, Willman CL, Gerhard DL, Mullighan CG*, Hunger SP* and Zhang J*. Rise and Fall of Subclones from Diagnosis to Relapse in Pediatric B-progenitor Acute Lymphoblastic Leukemia. *Nat Commun* 2015 6:6604 (PMCID:PMC4377644)

Manolio TA, Abramowicz M, Al-Mulla F, Anderson W, Balling R, Berger AC, Bleyl S, Chakravarti A, Chantratita W, Chisholm RL, W Dissanayake VH, Dunn M, Dzau VJ, Han BG, Hubbard T, Kolbe A, Korf B, Kubo M, Lasko P, Leego E, Mahasirimongkol S, Majumdar PP, Matthijs G, McLeod HL, Metspalu A, Meulien P, Miyano S, Naparstek Y, O'Rourke PP, Patrinos GP, Rehm HL, Relling MV, Rennert G, Rodriguez LL, Roden DM, Shuldiner AR, Sinha S, Tan P, Ulfendahl M, Ward R, Williams MS, L Wong JE,

Green ED, Ginsburg GS. Global implementation of genomic medicine: We are not alone. *Sci Transl Med*. 2015 7(290):290ps13. Review. (PMCID:PMC4898888)

McDaniel RB, Burlison JD, Baker DK, Hasan M, Robertson JJ, Hartford C, Howard SC, Sablauer A, Hoffman JM. Alert dwell time: introduction of a measure to evaluate interruptive clinical decision support alerts. *J Am Med Inform Assoc*. Apr 2016;23(e1):e138-41 (PMCID: PMC4954613)

McDaniel JM, Varley KE, Gertz J, Savic DS, Roberts BS, Bailey SK, Shevde LA, Ramaker RC, Lasseigne BN, Kirby MK, Newberry KM, Partridge EC, Jones AL, Boone B, Levy SE, Oliver PG, Sexton KC, Grizzle WE, Forero A, Buchsbaum DJ, Cooper SJ, Myers RM. Genomic regulation of invasion by STAT3 in triple negative breast cancer. *Oncotarget*. 2016 Dec 24.. [Epub ahead of print] PMID:28030809

Moon C, Zhang W, Ren A, Arora K, Sinha C, Yarlagadda S, Woodrooffe K, Schuetz JD, Valasani KR, de Jonge HR, Shanmukhappa SK, Shata MT, Buddington RK, Parthasarathi K, Naren AP. Compartmentalized Accumulation of cAMP near Complexes of Multidrug Resistance Protein 4 (MRP4) and Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Contributes to Drug-induced Diarrhea. *J Biol Chem*. 2015 May 1;290(18):11246-57 (PMCID:PMC4416832)

Morfouace M, Cheepala S, Jackson S, Albert YP, Kawauchi D, Shelat A, Fukuda Y, Sorrentino B, Schuetz JD* and Roussel MF*. (*co-corresponding authors) ABCG2 transporter expression impacts Group3 Medulloblastoma response to chemotherapy. *Cancer Res*. 2015 Sep 15; 75(18):3879-89 (PMCID: PMC4573843)

Morfouace, M., B. Nimmervoll, N. Boulos, Y.T. Patel, A. Shelat, B.B. Freeman, 3rd, G.W. Robinson, K. Wright, A. Gajjar, C.F. Stewart, R.J. Gilbertson, and M.F. Roussel. Preclinical studies of 5-fluoro-2'-deoxycytidine and tetrahydrouridine in pediatric brain tumors. *J Neurooncol*. 2015 Oct 30. (PMCID:PMC4718940)

Morgan JA, Lynch J, Panetta JC, Wang Y, Frase S, Bao J, Zhang J, Opferman JT, Janke L, Green DM, Chemaitilly W, and Schuetz JD. Apoptosome activation, an important molecular instigator in 6-mercaptopurine induced Leydig cell death. *Sci Rep*. 2015 Nov 5:16488. (PMCID: PMC4649703)

Moriyama T, Relling MV, and Yang JJ. Inherited Genetic Variation in Childhood Acute Lymphoblastic Leukemia. *Blood* 2015 125(26):3988-95 (PMCID: PMC4481591)

Moriyama T, Metzger ML, Wu G, Nishii R, Qian M, Devidas M, Yang W, Cheng C, Cao X, Quinn E, Raimondi S, Gastier-Foster JM, Raetz E, Larsen E, Martin PL, Bowman WP, Winick N, Komada Y, Wang S, Edmonson M, Xu H, Mardis E, Fulton R, Pui CH, Mullighan C, Evans WE, Zhang J, Hunger SP, Relling MV, Nichols KE, Loh ML, Yang JJ. Germline genetic variation in ETV6 and risk of childhood acute lymphoblastic leukaemia: a systematic genetic study. *Lancet Oncol*. 2015 16(16): 1659-66 (PMCID: PMC4684709)

Moriyama T, Nishii R, Perez-Andreu V, Yang W, Klussmann FA, Zhao X, Lin TN, Hoshitsuki K, Nersting J, Kihira K, Hofmann U, Komada Y, Kato M, McCorkle R, Li L, Koh K, Najera CR, Kham SK, Isobe T, Chen Z, Chiew EK, Bhojwani D, Jeffries C, Lu Y, Schwab M, Inaba H, Pui CH, Relling MV, Manabe A, Hori H, Schmiegelow K, Yeoh AE, Evans WE, Yang JJ. NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity. *Nat Genet*. 2016 Apr;48(4): 36+7-73 (PMCID:PMC5029084)

Mullighan CG, Jeha S, Pei D, Payne-Turner D, Coustan-Smith E, Roberts KG, Waanders E, Choi JK, Ma X, Raimondi SC, Fan Y, Yang W, Song G, Yang JJ, Inaba H, Downing JR, Leung WH, Bowman WP, Relling MV, Evans WE, Zhang J, Campana D, Pui CH. Outcome of children with hypodiploid ALL treated with risk-directed therapy based on MRD levels. *Blood*. 2015 126(26): 2896-9 (*PMCID:PMC4692147*)

Navid, F., C.E. Herzog, J. Sandoval, V.M. Daryani, C.F. Stewart, J. Gattuso, B. Mandrell, S. Phipps, W. Chemaitilly, A. Sykes, A.M. Davidoff, B.L. Shulkin, A. Bahrami, W.L. Furman, S. Mao, J. Wu, D. Schiff, B. Rao, and A. Pappo. Feasibility of Pegylated Interferon in Children and Young Adults with Resected High-Risk Melanoma. *Pediatr Blood Cancer*. 63(7):1207-13, 2016. (*PMCID: PMC4877209*).

Nieuweboer, A.J., E.S. de Morree, A.J. de Graan, A. Sparreboom, R. de Wit, and R.H. Mathijssen. Inter-patient variability in docetaxel pharmacokinetics: A review. *Cancer Treat Rev*, 2015. 41(7): p. 605-13. *PMID: 25980322*

Nieuweboer, A.J., M. Smid, A.M. de Graan, S. Elbouazzaoui, P. de Bruijn, F.A. Eskens, P. Hamberg, J.W. Martens, A. Sparreboom, R. de Wit, R.H. van Schaik, and R.H. Mathijssen. Role of genetic variation in docetaxel-induced neutropenia and pharmacokinetics. *Pharmacogenomics J*. 2015. *PMID: 26345519*

Nikanjam M, Stewart CF, Takimoto CH, Synold TW, Beaty O, Fouladi M, Capparelli EV. Population pharmacokinetic analysis of oxaliplatin in adults and children identifies important covariates for dosing. *Cancer Chemotherap Pharmacol* 75:495-503, 2015. (*PMCID: PMC4344382*)

Pabla, N., A.A. Gibson, M. Buege, S.S. Ong, L. Li, S. Hu, G. Du, J.A. Sprowl, A. Vasilyeva, L.J. Janke, E. Schlatter, T. Chen, G. Ciarimboli, and A. Sparreboom. Mitigation of acute kidney injury by cell-cycle inhibitors that suppress both CDK4/6 and OCT2 functions. *Proc Natl Acad Sci U S A*, 2015. 112(16): p. 5231-6. (*PMCID: PMC4413320*)

Pabla, N. and A. Sparreboom. CCR 20th anniversary commentary: BMS-247550-microtubule stabilization as successful targeted therapy. *Clin Cancer Res*, 2015. 21(6): p. 1237-9. (*PMCID: PMC4362690*)

Packer RJ, Rood BR, Turner DC, Stewart CF, Fisher M, Smith C, Young-Pouissant T, Goldman S, Lulla R, Banerjee A, Pollack I, Kun L, Boyett JM, Onar-Thomas A, Wu S, Fouladi M. Phase I and pharmacokinetic trial of PTC299 in pediatric patients with refractory or recurrent central nervous system tumors: a PBTC study. *J Neurooncol* 121(1):217-224, 2015. (*PMCID: PMC4330963*)

Park HW, Tse S, Yang W, Kelly HW, Kaste SC, Pui CH, Relling MV, Tantisira KG. A genetic factor associated with low final bone mineral density in children after a long-term glucocorticoids treatment *Pharmacogenomics J*. 2016 [Epub ahead of print] (*PMCID:PMC4980282*)

Pasternak AL, Crews KR, Caudle KE, Smith C, Pei D, Cheng C, Broeckel U, Gaur AH, Hankins J, Relling MV, Haidar CE. The impact of the UGT1A1*60 allele on bilirubin serum concentrations. *Pharmacogenomics*. 2016 Dec 14. [Epub ahead of print] *PMID:27967321 PMC Journal In Process*

Patel Y, Jacus M, Boulos N, Dapper J, David A, Vuppala P, Freeman III B, Mohankumar K, Throm S, Gilbertson R, Stewart CF. Preclinical examination of clofarabine in pediatric ependymoma: intratumoral concentrations insufficient to warrant further study. *Cancer Chemotherap Pharmacol* 2015 75:897-906. (*PMCID: PMC4420645*)

Patel, Y.T., M.O. Jacus, A.D. Davis, N. Boulos, D.C. Turner, P.K. Vuppala, B.B. Freeman, 3rd, R.J. Gilbertson, and C.F. Stewart. Simvastatin Hydroxy Acid Fails to Attain Sufficient Central Nervous System Tumor Exposure to Achieve a Cytotoxic Effect: Results of a Preclinical Cerebral Microdialysis Study. *Drug Metab Dispos*, 44:591-4, 2016. (PMCID: PMC4810761)

Paugh SW, Bonten E, Evans WE. Inflammasome mediated glucocorticoid resistance: the receptor rheostat. *Molecular and Cellular Oncology* Vol 3. Issue 1. 2015 Nov. 11:3(1):e1065947 (PMCID: PMC4845245)

Paugh SW, Bonten, EJ, Savic D, Ramsey LB, Thierfelder WE, Gurung P, Malireddi RK, Actis M, Mayasundari A, Min J, Coss DR, Laudermilk LT, Panetta JC, McCorkle JR, FanY, Crews KR, Stocco G, Wilkinson MR, Ferreira AM, Cheng C, Yang W, Karol SE, Fernandez CA, Diouf B, Smith C, Hicks JK, Zanut A, Giordanengo A, Crona D, Bianchi JJ, Holmfeltd L, Mullighan CG, den Boer ML, Pieters R, Jeha S, Dunwell TL, Latif F, Bhojwani D, Carroll WL, Pui CH, Myers RM, Guy RK, Kanneganti TD, Relling MV, Evans WE. NALP3 inflammasome up-regulation and CASP1 cleavage of the glucocorticoid receptor causes glucocorticoid resistance in leukemia cells. *Nat Genet*. 2015 47(6):607-14. (PMCID: PMC4449308)

Phoenix, T.N., D.M. Patmore, S. Boop, N. Boulos, M.O. Jacus, Y.T. Patel, M.F. Roussel, D. Finkelstein, L. Goumnerova, S. Perreault, E. Wadhwa, Y.J. Cho, C.F. Stewart, and R.J. Gilbertson. Medulloblastoma Genotype Dictates Blood Brain Barrier Phenotype. *Cancer Cell*, 29: 508-22, 2016. (PMCID: PMC4829447)

Pui C-H, Yang JJ, Hunger SP, Pieters R, Schrappe M, Biondi A, Vora A, Baruchel A, Silverman LB, Schmiegelow K, Escherich G, Horibe K, Benoit Y CM, Izraeli S, Yeoh AEJ, Liang D-C, Downing J, Evans WE, Relling MV, Mullighan CG. Childhood acute lymphoblastic leukemia: progress through collaboration. *J Clin Oncol* 2015 33(27): 2938-48 (PMCID: PMC4567699)

Pui CH, Pei D, Coustan-Smith E, Jeha S, Cheng C, Bowman WP, Sandlund JT, Ribeiro RC, Rubnitz JE, Inaba H, Bhojwani D, Gruber TA, Leung WH, Downing JR, Evans WE, Relling MV, Campana D. Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study. *Lancet Oncol*. 2015 16(4):465-74. (PMCID: PMC4612585)

Pui CH, Pei D, Ramondi S, Coustan-Smith E, Jeha S, Cheng C, Bowman W, Sandlund J, Ribeiro R, Rubnitz J, Inaba H, Gruber T, Leung W, Yang J, Downing J, Evans WE, Relling MV, Campana D. Clinical Impact of Minimal Residual Disease in Children with Different Subtypes of Acute Lymphoblastic Leukemia Treated with Response-Adapted Therapy. *Leukemia* 2016 Aug 18. [Epub ahead of print] PMID: 27560110

Qian M, Zhang H, Kham SK, Liu S, Jiang C, Zhao X, Lu Y, Goodings C, Lin TN, Zhang R, Moriyama T, Yin Z, Li Z, Quah TC, Ariffin H, Tan AM, Shen S, Bhojwani D, Hu S, Chen S, Zheng H, Pui CH, Yeoh AE, and Yang JJ. Whole transcriptome sequencing identified a distinct subtype of acute lymphoblastic leukemia with predominant Whole transcriptome sequencing identified a distinct subtype of acute lymphoblastic leukemia with predominant genomic abnormalities of *EP300* and *CREBBP*. *Genom Res*. 2016 Nov 30. pii: gr.209163.116. (epub ahead of print) (PMID: 27903646)

Quillivan RR, Burlison JD, Browne EK, Scott SD, Hoffman JM. Patient safety culture and the second victim phenomenon: Connecting culture to staff distress in nurses. *Jt Comm J Qual Patient Saf.* 2016 42 (8): 377-386. PMID: 27456420. *PMC Journal In Process*

Rau RE, Carroll AJ, Heerema NA, Arland L, Carroll WL, Winick NJ, Raetz EA, Loh ML, Yang W, Relling MV, Dai Y, Devidas M, Hunger SP. Klinefelter syndrome and 47,XYX syndrome in children with B cell acute lymphoblastic leukaemia. *Br J Haematol.* 2016 Jul 19. [Epub ahead of print] PMID: 27434379

Ramsey LB, Janke LJ, Payton MA, Cai X, Paugh SW, Karol SE, Kamdem LK, Cheng C, Williams RT, Jeha S, Pui CH, Evans WE, Relling MV. Antileukemic Efficacy of Continuous vs Discontinuous Dexamethasone in Murine Models of Acute Lymphoblastic Leukemia. *PLoS One.* 2015 10(8):e0135134. (PMCID: PMC4529108)

Relling MV and Evans WE: Pharmacogenomics in the Clinic. *Nature*, 2015. 526(7573): 343-50 (PMCID: PMC4711261)

Roberts, J.K., A.V. Birg, T. Lin, V.M. Daryani, J.C. Panetta, A. Broniscer, G.W. Robinson, A.J. Gajjar, and C.F. Stewart. Population Pharmacokinetics of Oral Topotecan in Infants and Very Young Children with Brain Tumors Demonstrates a Role of ABCG2 rs4148157 on the Absorption Rate Constant. *Drug Metab Dispos.* 44(7):1116-22, 2016. (PMCID: PMC4931885)

Robinson GW, Orr BA, Wu G, Gururangan S, Lin T, Qaddoumi I, Packer R, Goldman S, Prados M, Desjardins A, Chintagumpala M, Takebe N, Kaste SC, Rusch M, Allen SJ, Onar-Thomas A, Stewart CF, Fouladi M, Boyett JM, Gilbertson RJ, Curran T, Ellison DW, Gajjar A. Vismodegib exerts targeted efficacy against recurrent SHH-subgroup medulloblastoma: results from phase II pediatric brain tumor consortium studies – PBTC-025B and PBTC-032. *J Clin Oncol.* 2015 Aug 20;33(24):2646-54. (PMCID: PMC4534527)

Salloum, R., Hummel, T. R., Kumar, S. S., Dorris, K., Li, S., Lin, T., Daryani, V. M., Stewart, C. F., Miles, L., Poussaint, T. Y., Stevenson, C., Goldman, S., Dhall, G., Packer, R., Fisher, P., Pollack, I. F., Fouladi, M., Boyett, J. and Drissi, R. A molecular biology and phase II study of imetelstat (GRN163L) in children with recurrent or refractory central nervous system malignancies: a pediatric brain tumor consortium study. *J Neurooncol.* 129(3):443-51, 2016. *PMC Journal In Process*

Savic D, Partridge EC, Newberry K, Smith S, Meadows S, Roberts BS, Mackiewicz M, Mendenhall E, Myers RM. CETCh-seq: CRISPR epitope tagging ChIP-seq of DNA-binding proteins. *Genome Res* 25(10):1581-1589, 2015. PMID: 26355004. (PMCID: PMC4579343)

Savic D, Roberts BS, Carlestone JB, Partridge EC, White MA, Cohen BA, Cooper GM, Gertz J, Myers RM. Promoter-distal RNA polymerase II binding discriminates active from inactive CCAAT/enhancer binding protein beta binding sites. *Genome Res* 25(12):1791-1800, 2015. PMID: 26486725. (PMCID: PMC4665001)

Savic D, Ramaker RC, Roberts BS, Burwell TC, Dean EC, Meadows SK, Cooper SJ, Garabedian MJ, Gertz J, Myers RM. Distinct gene regulatory programs define the inhibitory effects of liver X receptors and PPAR γ on cancer cell proliferation. *Genome Med* 8(1):74, 2016. (PMCID: PMC4940857)

Schully SD, Lam TK, Dotson WD, Chang CQ, Aronson N, Birkeland ML, Brewster SJ, Boccia S, Buchanan AH, Calonge N, Calzone K, Djulbegovic B, Goddard KA, Klein RD, Klein TE, Lau J, Long R,

- Lyman GH, Morgan RL, Palmer CG, Relling MV, Rubinstein WS, Swen JJ, Terry SF, Williams MS, Khoury MJ. Evidence synthesis and guideline development in genomic medicine: current status and future prospects. *Genet Med*, 2015 17(1): 63-7 (PMCID: PMC4272332)
- Scott JR, Zhou Y, Cheng C, Ward DA, Swanson HD, Molinelli AR, Stewart CF, Navid F, Jeha S, Relling MV, Crews KR. Comparable efficacy with varying dosages of glucarpidase in pediatric oncology patients. *Pediatr Blood Cancer*. 2015 62(9):1518-22. (PMCID:PMC4770903)
- Shirasaka Y, Chaudhry AS, McDonald M, Prasad B, Wong T, Calamia JC, Fohner A, Thornton TA, Isoherranen N, Unadkat JD, Rettie AE, Schuetz EG, Thummel KE. Interindividual variability of CYP2C19-catalyzed drug metabolism due to differences in gene diplotypes and cytochrome P450 oxidoreductase content. *Pharmacogenomics J*. 2015 Sep 1. (PMCID: PMC4775436)
- Sinha C, Ren A, Arora K, Moon CS, Yarlagadda S, Woodrooffe K, Lin S, Schuetz JD, Ziady AG, Naren AP. PKA and actin play critical roles as downstream effectors in MRP4-mediated regulation of fibroblast migration. *Cell Signal*. 2015 Jul;27(7):1345-55. (PMCID:PMC4437852)
- Stock W, Diouf B, Crews KR, Pei D, Cheng C, Laumann K, Mandrekar SJ, Luger S, Advani A, Stone RM, Larson RA, Evans WE. An inherited genetic variant in CEP72 promoter predisposes to vincristine induced peripheral neuropathy in adults with acute lymphoblastic leukemia. *Clin Pharmacol Ther*. 2016 [Epub ahead of print] PMID:27618250
- Tanner JA, Prasad B, Claw KG, Stapleton P, Chaudhry A, Schuetz EG, Thummel KE, Tyndale RF. Predictors of variation in CYP2A6 mRNA, protein, and enzyme activity in a human liver bank: influence of genetic and non-genetic factors. *J Pharmacol Exp Ther*. 2017 Jan;360(1):129-139. (PMCID: PMC27815364)
- Thomson MM, Hines RN, Schuetz EG and Meibohm B. Expression Patterns of OATP 1B1 and OATP 1B3 Protein in Human Pediatric Liver. *Drug Metab Dispos*. 2016 Jul;44(7):999-1004. (PMCID: PMC4931892)
- Tracy TS, Chaudhry AS, Prasad B, Thummel KE, Schuetz EG, Zhong XB, Tien YC, Jeong H, Pan X, Shireman LM, Tay-Sontheimer J, Lin YS. Interindividual Variability in Cytochrome P450-Mediated Drug Metabolism. *Drug Metab Dispos*. 2016 Mar;44(3):343-51. (PMCID: PMC4767386)
- Vasilyeva A, Durmus S, Li L, Wagenaar E, Hu S, Gibson AA, Mani S, Sparreboom A, Baker SD, Schinkel AH. Hepatocellular shuttling and recirculation of sorafenib-glucuronide is dependent on Abcc2, Abcc3, and Oatp1a/1b. *Cancer Res*. 2015 Jul 1;75(13):2729-36 (PMCID: PMC4490028)
- Vilgelm AE, Pawlikowski JS, Liu Y, Hawkins OE, Davis TA, Smith J, Weller KP, Horton LW, McClain CM, Ayers GD, Turner DC, Essaka DC, Stewart CF, Sosman JA, Kelley MC, Ecsedy JA, Johnston JN, Richmond A. Mdm2 and Aurora A inhibitors synergize to block melanoma growth by driving apoptosis and immune clearance of tumor cells. *Cancer Research* 75:181-93, 2015. (PMCID: PMC4286469)
- Wang YM, Chai SC, Lin W, Chai X, Elias A, Wu J, Ong SS, Pondugula SR, Beard JA, Schuetz EG, Zeng S, Xie W, Chen T. Serine 350 of human pregnane X receptor is crucial for its heterodimerization with retinoid X receptor alpha and transactivation of target genes in vitro and in vivo. *Biochem Pharmacol*. 2015 Aug 15; 96(4):357-68. (PMCID: PMC4526351)

Watts CS, Sciasci JN, Pauley JL, Panetta JC, Pei D, Cheng C, Christensen CM, Mikkelsen TS, Pui CH, Jeha S, Relling MV. Prophylactic Trimethoprim-Sulfamethoxazole Does Not Affect Pharmacokinetics or Pharmacodynamics of Methotrexate. *J Pediatr Hematol Oncol.* 2016 Aug;33(6):449-52 (PMCID: PMC4955728)

Wetmore, C., Daryani, V. M., Billups, C. A., Boyett, J. M., Leary, S., Tanos, R., Goldsmith, K. C., Stewart, C.F., Blaney, S. M. and Gajjar, A. Phase II evaluation of sunitinib in the treatment of recurrent or refractory high-grade glioma or ependymoma in children: a children's Oncology Group Study ACNS1021. *Cancer Med.* 5(7):1416-24, 2016. (PMCID: PMC4944867)

Wilson CL, Liu L, Yang JJ, Kang G, Ojha RP, Neale G, Srivastava DK, Gurney JG, Hudson MM, Robison LL, Ness KK. Genetic and clinical factors associated with obesity among adult survivors of childhood cancer: A report from the St. Jude Lifetime cohort. *Cancer* 2015 [Epub ahead of print] (PMCID: PMC4641835)

Wright KD, Panetta JC, Onar-Thomas A, Reddick WE, Patay Z, Qaddoumi I, Broniscer A, Robinson G, Boop FA, Klimo P, Ward D, Gajjar A, Stewart CF. Delayed methotrexate excretion in infants and young children with primary central nervous system tumors and postoperative fluid collections. *Cancer Chemother Pharmacol* 75:27-35, 2015. (PMCID: PMC4282603)

Wright, K.D., V.M. Daryani, D.C. Turner, A. Onar-Thomas, N. Boulos, B.A. Orr, R.J. Gilbertson, C.F. Stewart, and A. Gajjar, Phase I study of 5-fluorouracil in children and young adults with recurrent ependymoma. *Neuro Oncol*, 2015. 17(12): p. 1620-7. (PMCID: PMC4633933)

Xu H, Zhang H, Yang W, Yadav R, Morrison AC, Qian M, Devidas M, Liu Y, Perez-Andreu V, Zhao X, Gastier-Foster JM, Lupo PJ, Neale G, Raetz E, Larsen E, Bowman WP, Carroll WL, Winick N, Williams R, Hansen T, Holm JC, Mardis E, Fulton R, Pui CH, Zhang J, Mullighan CG, Evans WE, Hunger SP, Gupta R, Schmiegelow K, Loh ML, Relling MV, Yang JJ. Inherited coding variants at the CDKN2A locus influence susceptibility to acute lymphoblastic leukaemia in children. *Nat Commun.* 2015 Jun 24; 6:7553. (PMCID: PMC4544058)

Xu H, Robinson GW, Huang J, Lim JY, Zhang H, Bass JK, Broniscer A2, Chintagumpala M, Bartels U, Gururangan S, Hassall T, Fisher M, Cohn R, Yamashita T, Teitz T, Zuo J, Onar-Thomas A, Gajjar A, Stewart CF, Yang JJ. Common variants in ACYP2 influence susceptibility to cisplatin-induced hearing loss. *Nat Genet.* 2015 Mar; 47 (3):263-6. (PMCID: PMC4358157)

Yang JJ, Landier W, Yang W, Liu C, Hageman L, Cheng C, Pei D, Chen Y, Crews KR, Kornegay NM, Wong FL, Evans WE, Pui C-H, Bhatia S, Relling MV. Inherited *NUDT15* variant is a genetic determinant of mercaptopurine intolerance in children with acute lymphoblastic leukemia. *J Clin Oncol* 2015. 33(11): 1235-42 (PMCID: PMC4375304)

Yang W, Wu G, Broeckel U, Smith CA, Turner V, Haidar CE, Wang S, Carter R, Karol SE, Neale G, Crews K, Yang JJ, Mullighan CG, Downing JR, Evans WE, Relling MV. Comparison of genome sequencing and clinical genotyping for pharmacogenes. *Clin Pharmacol Ther.* 2016 Jun 17. doi: 10.1002/cpt.411. [Epub ahead of print] PMID:27311679

Yasuda K, Cline C, Lin YS, Scheib R, Ganguly S, Thirumaran R, Chaudhry AS, Kim RB, Schuetz EG. In Vivo Imaging of Human MDR1 Transcription in the Brain and Spine of MDR1-Luciferase Reporter Mice. *Drug Metab Dispos.* 2015 Nov;43(11):1646-54. (PMCID: PMC4613952)

Zhang J, McCastlain K, Yoshihara H, Xu B, Chang Y, Churchman ML, Wu G, Li Y, Wei L, Iacobucci I, Liu Y, Qu C, Wen J, Edmonson M, Payne-Turner D, Kaufmann KB, Takayanagi SI, Wienholds E, Waanders E, Ntziachristos P, Bakogianni S, Wang J, Aifantis I, Roberts KG, Ma J, Song G, Easton J, Mulder HL, Chen X, Newman S, Ma X, Rusch M, Gupta P, Boggs K, Vadodaria B, Dalton J, Liu Y, Valentine ML, Ding L, Lu C, Fulton RS, Fulton L, Tabib Y, Ochoa K, Devidas M, Pei D, Cheng C, Yang J, Evans WE, Relling MV, Pui CH, Jeha S, Harvey RC, Chen IL, Willman CL, Marcucci G, Bloomfield CD, Kohlschmidt J, Mrózek K, Paietta E, Tallman MS, Stock W, Foster MC, Racevskis J, Rowe JM, Luger S, Kornblau SM, Shurtleff SA, Raimondi SC, Mardis ER, Wilson RK, Dick JE, Hunger SP, Loh ML, Downing JR, Mullighan CG; St. Jude Children's Research Hospital–Washington University Pediatric Cancer Genome Project. Deregulation of DUX4 and ERG in acute lymphoblastic leukemia. *Nat Genet.* 2016 Dec;48(12):1481-1489. (PMCID: PMC5144107)

Zhang Y, Li F, Wang Y, Fang Z, Frank M, Calabrese C, Krausz KW, Neale G, Frase S, Vogel P, Rock CO, Gonzalez FJ and Schuetz JD. Maternal bile acid transporter deficiency promotes neonatal demise. *Nat Commun.* 2015 Sep 29; 6:8186. doi: 10.1038/ncomms9186. (PMCID: PMC4598356). **2015 Selected to Faculty 1000 Must Read.**

Zhu L, Finkelstein D, Gao C, Shi L, Wang Y, López-Terrada D, Wang K, Utlely S, Pounds S, Neale G, Ellison D, Onar-Thomas A, Gilbertson RJ. Multi-organ mapping of cancer risk. *Cell* 166(5): 1132-46, 2016. (PMCID: PMC5067024)

Zimmerman, E.I., A.A. Gibson, S. Hu, A. Vasilyeva, S.J. Orwick, G. Du, G.P. Mascara, S.S. Ong, T. Chen, P. Vogel, H. Inaba, M.L. Maitland, A. Sparreboom, and S.D. Baker. Multikinase Inhibitors Induce Cutaneous Toxicity through OAT6-Mediated Uptake and MAP3K7-Driven Cell Death. *Cancer Res*, 2015. 76(1):117-26 (PMCID:PMC4713045)

